BioSpace News Archive

CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biopharmaceutical company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, announced today an interview with Company Chair and CEO N. Scott Fine will air on The RedChip Money Report television program

CURE Media Group, which reaches over 1 million patients, survivors and caregivers across an industry-leading multimedia platform devoted solely to cancer updates and research, will host several patient-focused sessions Saturday, Nov. 9, from 7:15 a.m.-5:15 p.m. at the New York Marriott Marquis in New York City during the Physicians’ Education Resource® 14th Annual New York Lung Cancers Symposium®.

Fourth Annual Fundraiser for Childhood Cancer Research is Kicking Off During Childhood Cancer Awareness Month on Sept. 9

Canopy Health announced today an expansion of its collaboration with Health Net.

According to the Massachusetts Department of Public Health, in the first six months of 2019 alone, there were 611 confirmed opioid-related overdose deaths in the Commonwealth – more than three per day.

Invitae Corporation (NYSE: NVTA) today announced its intention to offer, subject to market conditions and other factors, $200.0 million aggregate principal amount of convertible senior notes due 2024 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

Dicerna™ Pharmaceuticals, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 29,000 shares of common stock to be distributed among four new employees, with a grant date of September 3, 2019.

First regulatory approval of NERLYNX in Latin America.

All of the shares in the offering are to be sold by TransEnterix.

Presentation Scheduled for Monday, September 9 at 11:50 AM Eastern Time